Evidence map›Paper›PMID 42611417›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant.

Chen Nahshon, Leen Fahoum, Dana Hadar, Hila Cohen, Rachel Michaelson-Cohen, Shira Regev, Meirav Schmidt, Wisam Assaf, Steven A Narod, Yakir Segev

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chen NahshonThe Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel. csarshalom@technion.ac.il.ORCID http://orcid.org/0000-0003-0786-6934
Leen FahoumThe Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Dana HadarResearch Authority, Clalit Health Care Organization, Carmel Medical Center, Haifa, Israel.
Hila CohenResearch Authority, Clalit Health Care Organization, Carmel Medical Center, Haifa, Israel.
Rachel Michaelson-CohenMedical Genetics Institute, Department of and Gynecology, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Shira RegevThe Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Meirav SchmidtThe Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Wisam AssafThe Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Steven A NarodDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Yakir SegevThe Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen with BRCA1/2 pathogenic variants face increased risks of breast and ovarian cancers. Our study aimed to evaluate the impact of hormonal contraceptive use on these risks.

methodsThis matched cohort study included 1677 women who were found to carry a BRCA1/2 pathogenic variant. A Cox proportional hazards model was used to estimate hazard ratios associated with oral contraceptive use and with levonorgestrel-releasing intrauterine device use.

resultsAmong BRCA1 carriers (n = 990), oral contraceptive use was not associated with breast cancer risk (HR = 0.90, 95% CI 0.77-1.05, p = 0.2). Among BRCA2 carriers (n = 687), oral contraceptive use was associated with reduced breast cancer risk (HR = 0.80, 95% CI 0.65-0.99, p = 0.04), although duration-stratified analyses did not demonstrate a consistent dose-response relationship. Oral contraceptive use was associated with a decrease in the risk of ovarian cancer in BRCA2 carriers (HR = 0.57, 95% CI 0.35-0.94, p = 0.028), with the strongest protective effect observed among BRCA2 carriers who used an oral contraceptive for more than 5 years (HR = 0.13; 95% CI 0.02-0.92). The protective effect of oral contraceptive use was less profound for BRCA1 carriers. The use of a levonorgestrel-releasing intrauterine device was not associated with breast or ovarian cancer risk.

conclusionThe use of an oral contraceptive was associated with reduced risks of breast and ovarian cancer among BRCA2 carriers, although the observed association with breast cancer should be interpreted cautiously given the absence of a consistent duration-response pattern. There was no increase in the risk of breast cancer among BRCA1 carriers who used an oral contraceptive. No association with either cancer was found among users of a levonorgestrel-releasing intrauterine device.

Indexed as

BRCABreast cancerContraceptivesIUDOvarian cancerPills

Identifiers

PMID42611417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.